KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in ReceivablesDeferred TaxesDepreciation & Amortization (CF)Exchange Rate EffectFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeNon-cash ItemsShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Xenon Pharmaceuticals (XENE) Non-cash Items (2016 - 2025)

Xenon Pharmaceuticals (XENE) has disclosed Non-cash Items for 13 consecutive years, with $137.7 million as the latest value for Q4 2025.

  • On a quarterly basis, Non-cash Items rose 23.79% to $137.7 million in Q4 2025 year-over-year; TTM through Dec 2025 was $137.7 million, a 23.79% increase, with the full-year FY2025 number at $137.7 million, up 23.79% from a year prior.
  • Non-cash Items was $137.7 million for Q4 2025 at Xenon Pharmaceuticals, up from $6.4 million in the prior quarter.
  • In the past five years, Non-cash Items ranged from a high of $200.1 million in Q4 2023 to a low of $2.8 million in Q1 2021.
  • A 5-year average of $38.5 million and a median of $5.6 million in 2024 define the central range for Non-cash Items.
  • Peak YoY movement for Non-cash Items: skyrocketed 246.0% in 2021, then crashed 44.43% in 2024.
  • Xenon Pharmaceuticals' Non-cash Items stood at $105.4 million in 2021, then skyrocketed by 39.67% to $147.2 million in 2022, then surged by 35.94% to $200.1 million in 2023, then plummeted by 44.43% to $111.2 million in 2024, then grew by 23.79% to $137.7 million in 2025.
  • Per Business Quant, the three most recent readings for XENE's Non-cash Items are $137.7 million (Q4 2025), $6.4 million (Q3 2025), and $6.3 million (Q2 2025).